Press Trust Of India / New Delhi Aug 20, 2009, 01:10 IST
Panacea Biotec today bagged a three-year contract worth over Rs 1,067 crore ($222.37 million) from Unicef for supplying its EasyFive vaccine.
EasyFive, a combination of five vaccines, is used in immunising children against five diseases — Diphtheria, Tetanus, Pertussis, Hepatitis B and Hemophilus Influenza. “This award is one of the growth drivers which would have a significant impact on our overall performance in the coming years,” Panacea Biotec Joint Managing Director Rajesh Jain said in a statement.
Pentavalent vaccines are used by agencies like United Nations Children’s Fund to vaccinate millions of children in the developing world.
The company claims EasyFive is the world’s first fully liquid pentavalent vaccine. The drug was introduced in India by Panacea Biotec in January 2005. The company received the pre-qualification for EasyFive by World Health Organization (WHO) in July last year.
Under its overall strategy to garner a firm foothold in various immunisation programmes across the globe, Panacea Biotec has partnered with WHO and Unicef in their effort to maximise coverage of vaccines.
Shares of Panacea advanced 5 per cent to hit its upper trading limit of Rs 174 on the Bombay Stock Exchange.
Hello
I am Deepak Sharma. how can i support through the provide service as a contractor of any type of cleaning or civil jobs at East Singhbhum,Jharkhand(India).My contact No.09334643763.
I am a very small contractor of Jamshedpur but i want support in my city or my District.My financial status is not good but me or my heart want do something through my job.
Content Guide
